medigraphic.com

2003, Number 3

<< Back Next >>

Bioquimia 2003; 28 (3)

Human's Toxoplasmosis

Martín-Hernández I, García-Izquierdo SM

Language: Spanish
References: 57
Page: 19-27
PDF size: 205.19 Kb.


ABSTRACT

Toxoplasmosis is an infection caused by intracellular parasite Toxoplasma gondii. This microorganism is able of infect diversity of mammals and birds, including humans. This infection is expanded worldwide and its seroprevalence depends on the location and age of the population. It usually stays asymptomatic and when the symptoms are present the manifestations are depend on the organ or system of organ affected. The parasite exists in three infectious forms: oocysts, tachyzoites y bradyzoites. Its life cycle occurs sexual and asexually. The infection transmission is generally produced digestive way, although it can occur by transplacental way too. The parenteral, respiratory, mucosal and cutaneous ways are reported, but are less frequent. In the immunocompetent hosts mucosal, cellular, and humoral immune responses play an important role in controlling of parasite replication. The laboratory techniques are essential for the etiologic diagnosis and there are several procedures for direct demonstration parasite and other indirect ones for specific antibodies searching. The treatment is a motive of preoccupation and controversy, and although there is not a totally satisfactory treatment, infection is treated with diverse drugs.


REFERENCES

  1. Botero D, Restrepo M. Toxoplasmosis. En: ParasitosisHumana. 2a ed. Medellín: Corporación para Investiga-ciones Biológicas; 1992. p. 231-48.

  2. Kasper LH. Toxoplasma infection. En: Harrison’s principlesof internal medicine. 14 ed. New York: McGraw-HillCompanies Inc; 1998. p. 1197-202

  3. Remington JS, McLeod R, Desmonts G. Toxoplasmosis.En: Infectious diseases of the fetus and newborn. 5a ed.Philadelphia: W.B. Saunders; 2001. p. 205-346.

  4. Masur H. Toxoplasmosis. En: Cecil Tratado de MedicinaInterna. 19 ed. México: Interamericana. Vol.2; 1994.p.2310-14.

  5. Okome M, Mbounja ME, Kombila M. Spectrum ofopportunistic infections in subjects infected with HIV.Santé 2000; 10: 329-37.

  6. Oréfice F, Bonfioli AA. Uveíte clínica e cirúrgica. En:Toxoplasmose. Rio de Janeiro: Editora Cultura Médica;2000. p. 619-80.

  7. Dubey JP, Speer CA, Shen SK, Kwok OCH, Blixt. Oocyst-induced murine toxoplasmosis: life cycle, pathogenecity,and stage conversion in mice fed Toxoplasma gondii cyst.J Parasitol 1997; 83: 870-82.

  8. Boothroyd JC, Hehl A, Knoll LJ, Manger IE. The surfaceof Toxoplasma: more and less. Intern J Parasitol 1998;28: 3-9.

  9. Speer CA, Clark S y Dubey JP. Ultraestructure of theoocysts, sporocysts, and sporozoites of Toxoplasmagondii. J Parasitol 1998; 84: 505-12.

  10. 10.Thulliez P. Ciclo de Toxoplasma gondii. En: Toxoplasmosisy diagnóstico. Madrid: Coimpress SA; 1996. p. 5-6.

  11. Jerome ME, Radke JR, Bohne W, Roos DS, White MW.Toxoplasma gondii bradizoytes form spontaneously duringsporozoite-initiated development. Infect Immun 1998;66: 4838-44.

  12. Acha PN y Szyfres B. Toxoplasmosis. En: Zoonosis yenfermedades transmisibles comunes al hombre y losanimales. 2a ed. Washington DC: Organización Paname-ricana de la Salud; 1989. p.646-58.

  13. Chatterton JM. Pregnancy. En: Human toxoplasmosis.New York: Oxford Medical Publications; 1992. p. 144-83.

  14. Petersen E, Pollak A, Reiter-Owona I. Recent trends inresearch on congenital toxoplasmosis. Int J Parasitol 2001;31:115-44.

  15. Anthonys H, Clifford L. Human Immunodeficiency virus(HIV) disease: AIDS and related disorders. En: Harrison’sprinciples of internal medicine. 14 ed. New York:McGraw-Hill Companies Inc; 1998. CD-ROM.

  16. Chardes T, Bout D. Mucosal immune response intoxoplasmosis. Res Immunol 1993; 144 : 57-60.

  17. Jenum PA, Stray-Pedersen B. Development of specificimmunoglobulins G, M and a following primaryToxoplasma gondii infection in pregnant women. J ClinMicrobiol 1998; 36: 2907-13.

  18. Denkers EY, Gazzinelli RT. Regulation and function ofT-cell-mediated immunity during Toxoplasma gondiiinfection. Clin Microbiol Rev 1998; 11: 569-88.

  19. Montoya JG, Remington JS. Studies on the serodiagnosisof toxoplasmic lymphadenitis. Clin Infect Dis 1995; 20:781-9.

  20. Nojimoto ITI, Hoshino S, Nagasse TK, Camargo ME.Lectins for the detection of IgM antibodies to T. gondiiin the diagnosis of acute toxoplasmosis by immuno-fluorescence test. Rev Inst Med Trop 1987; 29: 354-60.

  21. Sabauste CS, de Waal R, Fuh F. Role of CD80 (B7.1)and CD 86 (B7.2) in the immune response to an intra-cellular pathogen. J Immunol 1998; 160: 1831-40.

  22. Scharton-Kersten TM, Wynn TA, Denkers EY, Bala S,Showe L, Grunvald E, et al. In the absence of endogenousIFN-g mice develop unimpaired IL-12 responses toToxoplasma gondii while failing to control acute infection.J Immunol 1996; 157: 4045-54.

  23. Sánchez R, Sánchez E, Rodríguez N. Interleucina 12 con-tra enfermedades infecciosas. Rev Cubana Med 2001;40: 118-21.

  24. Neyer LE, Grunig G, Fort M, Remington JS, Rennick D,Hunter CA. Role of interleukin-10 in regulation ofT-cell-dependent and T-cell-independent mechanismsof resistance to Toxoplasma gondii. Infect Immun1997; 1675-82.

  25. Gazzinelli RT, Wysocka M, Hieny S, Scharton-Kersten T,Cheever A, Kuhn R, et al. In the absence of endogenousIL-10, mice acutely infected with Toxoplasma gondiisuccumb to a lethal immune response dependent uponCD4+ T cells and accompanied by overproduction ofIL-12, IFN-γ, and TNF-α. J Immunol 1996; 157: 798-805.

  26. Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A.Synergistic role of CD4+ and CD8+ T lymphocites in IFN-γproduction and protective immunity induced by anattenuated Toxoplasma gondii vaccine. J Immunol 1991;146: 286-92.

  27. Dimier I, Bout DT. Interferon γ activated primaryenterocytes inhibit Toxoplasma gondii replication: a rolefor intracellular iron. Immunology 1998; 94: 488-95.

  28. Dimier I, Bout DT. Inhibition of Toxoplasma gondiireplication in IFN-γ activated human intestinal epithelialcells. Immunol Cell Biol 1997; 75: 511-14.

  29. Benenson A. Toxoplasmosis congénita. En: El control delas enfermedades transmisibles en el hombre. 15 ed. In-forme Oficial de la Asociación Estadounidense de SaludPública: Organización Panamericana de la Salud; 1992.p. 520-3.

  30. Allain JP, Palmer CR, Pearson G. Epidemiological studyof latent and recent infection by Toxoplasma gondii inpregnant women from a regional population in the U.K.J Infect 1998; 36: 189-96.

  31. Morten L, Larcen SO, Petersen E. Prevalence, incidenceand geographical distribution of Toxoplasma antibodiesin pregnant women in Denmark. Scand J Infect Dis 1993;25: 751-6.

  32. Lappalainen M, Koskela P, Hedman K, Teramo K,Ammala P, Hiilesmaa V, et al. Incidence of primaryToxoplasma infections during pregnancy in SouthernFinland: A prospective cohort study. Scand J Infect Dis1992; 24: 97-104.

  33. Lebech M, Larsen SO, Petersen E. Prevalence, incidenceand geographical distribution of Toxoplasma gondiiantibodies in pregnant women in Denmark. Scand J Dis1993; 25: 751-3.

  34. Jenum PA, Stray-Pedersen B, Melby KK, Kapperud G,Whitelaw A, Eskild A, et al. Incidence of Toxoplasmagondii infection in 35 940 pregnant women in Norwayand pregnancy outcome for infected women. J ClinMicrobiol 1998; 36: 2900-06.

  35. Jenum PA, Kapperud G, Stray-Pedersen B, Melby KK,Eskild A, Eng J. Prevalence of Toxoplasma gondii specificimmunoglobulin G antibodies among pregnant womenin Norway. Epidemiol Infect 1998; 120: 87-92.

  36. Boweman RJ. Seroprevalence of Toxoplasma gondii inrural Indian: A preliminary study. Transact Royal SocTrop Med Hyg 1991; 85: 622.

  37. Logar J, Novak-Antolic Z, Zore A, Cerar V, Likar M.Incidence of the congenital toxoplasmosis in the Republicof Slovenia. Scand J Infect Dis 1992; 24: 105-08.

  38. Dupouy CJ, Lavareda S, Maslo C. Distribución mundialde la prevalencia de la inmunidad toxoplásmica. MedMal Infect 1993; 23: 139-47.

  39. Fernández JL. Screening technology development-TheCuban Experience. 8th International Symposium onNeonatal Screening and Inaural Meeting of theInternational Society for Neonatal Sreening. AbstractsBook, Sidney, Australia. 1991.

  40. López R, Fano R, Contreras R, Font L. Anticuerpos IgGanti-Toxoplasma gondii en cubanos donantes de sangre.Rev Latin Amer Microbiol 1993; 35: 207-10.

  41. López R, Pérez X, Guerra E, Herrera R, Acosta C. Toxo-plasmosis entre mujeres embarazadas en Ciudad de laHabana. Biomed 1993; 13 (4): 173-8.

  42. López R, Pérez X, Collazo JE, Acosta C. Anticuerposanti-Toxoplasma gondii en niños cubanos. Biomed 1993;13: 183-6.

  43. Collazo JE, Lopez R, Ginorio D, Llamos R, Contreras R.Anticuerpos IgG anti-Toxoplasma gondii en pacientescon síntomas atribuíbles a toxoplasmosis. Biomed 1993;13: 179-82.

  44. González T, Bacallao J, García C, Molina JR. Prevalenciade anticuerpos anti-Toxoplasma gondii en una pobla-ción de mujeres embarazadas en Cuba. Gac Med Mex1991; 131: 499-503.

  45. Acosta C, Pérez X, García R. Presencia de anticuerposIgG anti-Toxoplasma gondii en embarazadas residentesen Ciudad de la Habana. Rev Biomed 2001; 12: 250-54.

  46. Markell EK, Voge M, John DT. Otros protozoos de lasangre y los tejidos. En: Parasitología médica. 6a ed.Madrid: Interamericana; 1990. p. 104-51.

  47. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii:from animals to humans. Int J Parasitol 2000; 30:1217-58.

  48. Jenum PA, Holberg-Petersen M, Melby KK, Stray-Pedersen B. Diagnosis of congenital Toxoplasma gondiiinfection by polymerase chain reaction (PCR) onamniotic fluid samples. APMIS 1998; 106: 680-6.

  49. Jenum PA, Stray-Pedersen B, Gudersen A. Improved diag-nosis of primary Toxoplasma gondii infection in earlypregnancy by determination of anti-Toxoplasmaimmunoglobulin G avidity. J Clin Microbiol 1997; 35:1972-7.

  50. Eaton RB. Evaluation of neonatal Toxoplasma gondiiIgM FEIA. J Clin Microbiol 1996; 34: 3147-50.

  51. Foudrinier F, Marx-Chemla C, Aubert D, Bonhomme A,Pinon JM. Value of specific immunoglobulin A detectionby two immunocapture assay in the diagnosis oftoxoplasmosis. Eur J Clin Microbiol Infect Dis 1995; 14:585-90.

  52. Machín R, De la Cruz F, Pividal J. Comparación del ELISAcon las técnicas de inmunofluorescencia indirecta y fija-ción de complemento para el diagnóstico de latoxoplasmosis. Rev Cub Med Trop 1985; 37: 269-77.

  53. López O. Estudio de dos técnicas inmunoparasitológicaspara la detección de anticuerpos anti-Toxoplasma gondii.Tesis. La Habana: Universidad de la Habana; 1991.

  54. Iñigo MA, Sánchez A, González M. Profilaxis de las in-fecciones oportunistas asociadas al SIDA. Farm Hosp1996; 20: 337-42.

  55. Valdés MC, Díaz AG, Svarch N. Actualidades en el trata-miento y profilaxis de la toxoplasmosis. Rev Cubana MedGen Inegr 1996;12: 4-6

  56. Kapperud G, Jenum PA, Stray-Pedersen B, Melby KK,Eskild A, Eng J. Risk factors for Toxoplasma gondiiinfection in pregnancy. Am J Epidemiol 1996; 144:405-12.

  57. Payen MC, Dewit S, Sommereijns B, Clumerk N. Acontrolled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystiscarinii, pneumonia and toxoplasmosis in patients withAIDS. Biomed Pharmacother 1997; 51: 439-45.




2020     |     www.medigraphic.com